Vebeglogene autotemcel (Lantu Biopharma)

N/A

Report date: 2024/07/20 20:00:10

Base Information

Drug NameVebeglogene autotemcel (Lantu Biopharma)

Drug Alias NameBeta-globin lentiviral vector transduced autologous HSCs (Lantu Biopharma)

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy

Mechanisms of ActionStem cell replacementsGene transference

TargetsNot applicable

Therapy Area/Indicationsbeta-Thalassemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesLantu Biopharma Inc

China Registration ClassN/A

Develop Information

Active CompaniesLantu Biopharma Inc

Inactive CompaniesN/A

Active Indicationsbeta-Thalassemia

Inactive IndicationsN/A

Other Information

ATC CodeN/A